Menú Cerrar

Serum adiponectin is a potential biomarker for metabolic syndrome in peri-and postmenopausal women

Wattanapol P1Vichinsartvichai P1Sakoonwatanyoo P2.

Gynecol Endocrinol. 2020 Apr 1:1-6. doi: 10.1080/09513590.2020.1742688. [Epub ahead of print]



Metabolic syndrome (MetS) increases its prevalence during menopausal period and there is no appropriate marker for screening before the cardiovascular damage begun. This study aims to find the diagnostic accuracy and the appropriate cutoff level of serum adiponectin for the screening of MetS in peri- and postmenopausal women. Women aged at least 40 years old attending health checkup clinic were recruited. Anthropometric measurements, blood pressure, MENQOL, and blood chemistry (glucose, adiponectin, HDL-C, LDL-C, and TG) were recorded. MetS was defined by JIS 2009 criteria. 290 peri-and postmenopausal women mean age 54.25 ± 8.6 years were recruited. 66% was postmenopause and 21.4% of them has MetS. The socioeconomic and lifestyle factors seem similar among women with and without MetS. In the participants with MetS, the prevalence of abdominal obesity was higher (96.8% vs 49.6%, p < .001, respectively) and more prevalence of android fat distribution pattern was observed (76.2% vs 36%, p < .001, respectively). Serum adiponectin was significantly lower in women with MetS (6.0 ± 4.6 vs 9.2 ± 5.2 μg/mL, p < .001 in MetS and non-MetS, respectively).

 Serum adiponectin is a good biomarker for MetS and we recommend the cutoff level of serum adiponectin lower than 7.15 μg/mL for screening of MetS (AUC (95% CI) of = 0.72 (0.64-0.79), p < .001).